Immunoconjugates: Combinations of diagnostic or therapeutic substances linked with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; or ANTIGENS. Often the diagnostic or therapeutic substance is a radionuclide. These conjugates are useful tools for specific targeting of DRUGS and RADIOISOTOPES in the CHEMOTHERAPY and RADIOIMMUNOTHERAPY of certain cancers.Antigens, CD30: A member of the tumor necrosis factor receptor superfamily that may play a role in the regulation of NF-KAPPA B and APOPTOSIS. They are found on activated T-LYMPHOCYTES; B-LYMPHOCYTES; NEUTROPHILS; EOSINOPHILS; MAST CELLS and NK CELLS. Overexpression of CD30 antigen in hematopoietic malignancies make the antigen clinically useful as a biological tumor marker. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.Lymphoma, Large-Cell, Anaplastic: A systemic, large-cell, non-Hodgkin, malignant lymphoma characterized by cells with pleomorphic appearance and expressing the CD30 ANTIGEN. These so-called "hallmark" cells have lobulated and indented nuclei. This lymphoma is often mistaken for metastatic carcinoma and MALIGNANT HISTIOCYTOSIS.Hodgkin Disease: A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.Cardiotoxins: Agents that have a damaging effect on the HEART. Such damage can occur from ALKYLATING AGENTS; FREE RADICALS; or metabolites from OXIDATIVE STRESS and in some cases is countered by CARDIOTONIC AGENTS. Induction of LONG QT SYNDROME or TORSADES DE POINTES has been the reason for viewing some drugs as cardiotoxins.Lymphoma, Primary Effusion: A rare neoplasm of large B-cells usually presenting as serious effusions without detectable tumor masses. The most common sites of involvement are the pleural, pericardial, and peritoneal cavities. It is associated with HUMAN HERPESVIRUS 8, most often occurring in the setting of immunodeficiency.Peripheral Nervous System Diseases: Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves.Clinical Trials, Phase I as Topic: Works about studies performed to evaluate the safety of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in healthy subjects and to determine the safe dosage range (if appropriate). These tests also are used to determine pharmacologic and pharmacokinetic properties (toxicity, metabolism, absorption, elimination, and preferred route of administration). They involve a small number of persons and usually last about 1 year. This concept includes phase I studies conducted both in the U.S. and in other countries.Hematologic Neoplasms: Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.Antineoplastic Agents: Substances that inhibit or prevent the proliferation of NEOPLASMS.Recurrence: The return of a sign, symptom, or disease after a remission.Oligopeptides: Peptides composed of between two and twelve amino acids.Antigens: Substances that are recognized by the immune system and induce an immune reaction.Antigens, CD: Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.Antigens, CD8: Differentiation antigens found on thymocytes and on cytotoxic and suppressor T-lymphocytes. CD8 antigens are members of the immunoglobulin supergene family and are associative recognition elements in MHC (Major Histocompatibility Complex) Class I-restricted interactions.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Antigens, Neoplasm: Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.Antigens, CD3: Complex of at least five membrane-bound polypeptides in mature T-lymphocytes that are non-covalently associated with one another and with the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL). The CD3 complex includes the gamma, delta, epsilon, zeta, and eta chains (subunits). When antigen binds to the T-cell receptor, the CD3 complex transduces the activating signals to the cytoplasm of the T-cell. The CD3 gamma and delta chains (subunits) are separate from and not related to the gamma/delta chains of the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA).Antigens, Surface: Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated.Antigens, Bacterial: Substances elaborated by bacteria that have antigenic activity.Antigens, CD38: A bifunctional enzyme that catalyzes the synthesis and HYDROLYSIS of CYCLIC ADP-RIBOSE (cADPR) from NAD+ to ADP-RIBOSE. It is a cell surface molecule which is predominantly expressed on LYMPHOID CELLS and MYELOID CELLS.Antigens, CD34: Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.Antigens, CD19: Differentiation antigens expressed on B-lymphocytes and B-cell precursors. They are involved in regulation of B-cell proliferation.Antigens, CD40: A member of the tumor necrosis factor receptor superfamily with specificity for CD40 LIGAND. It is found on mature B-LYMPHOCYTES and some EPITHELIAL CELLS, lymphoid DENDRITIC CELLS. Evidence suggests that CD40-dependent activation of B-cells is important for generation of memory B-cells within the germinal centers. Mutations of the gene for CD40 antigen result in HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 3. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.CD40 Ligand: A membrane glycoprotein and differentiation antigen expressed on the surface of T-cells that binds to CD40 ANTIGENS on B-LYMPHOCYTES and induces their proliferation. Mutation of the gene for CD40 ligand is a cause of HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 1.Antigens, CD20: Unglycosylated phosphoproteins expressed only on B-cells. They are regulators of transmembrane Ca2+ conductance and thought to play a role in B-cell activation and proliferation.Antigens, Viral: Substances elaborated by viruses that have antigenic activity.Antigens, CD28: Costimulatory T-LYMPHOCYTE receptors that have specificity for CD80 ANTIGEN and CD86 ANTIGEN. Activation of this receptor results in increased T-cell proliferation, cytokine production and promotion of T-cell survival.Antigens, CD44: Acidic sulfated integral membrane glycoproteins expressed in several alternatively spliced and variable glycosylated forms on a wide variety of cell types including mature T-cells, B-cells, medullary thymocytes, granulocytes, macrophages, erythrocytes, and fibroblasts. CD44 antigens are the principle cell surface receptors for hyaluronate and this interaction mediates binding of lymphocytes to high endothelial venules. (From Abbas et al., Cellular and Molecular Immunology, 2d ed, p156)Antigens, CD7: Differentiation antigens expressed on pluripotential hematopoietic cells, most human thymocytes, and a major subset of peripheral blood T-lymphocytes. They have been implicated in integrin-mediated cellular adhesion and as signalling receptors on T-cells.Antigens, CD14: Glycolipid-anchored membrane glycoproteins expressed on cells of the myelomonocyte lineage including monocytes, macrophages, and some granulocytes. They function as receptors for the complex of lipopolysaccharide (LPS) and LPS-binding protein.Antigens, CD2: Glycoprotein members of the immunoglobulin superfamily which participate in T-cell adhesion and activation. They are expressed on most peripheral T-lymphocytes, natural killer cells, and thymocytes, and function as co-receptors or accessory molecules in the T-cell receptor complex.CD4-CD8 Ratio: Ratio of T-LYMPHOCYTES that express the CD4 ANTIGEN to those that express the CD8 ANTIGEN. This value is commonly assessed in the diagnosis and staging of diseases affecting the IMMUNE SYSTEM including HIV INFECTIONS.Antigens, CD5: Glycoproteins expressed on all mature T-cells, thymocytes, and a subset of mature B-cells. Antibodies specific for CD5 can enhance T-cell receptor-mediated T-cell activation. The B-cell-specific molecule CD72 is a natural ligand for CD5. (From Abbas et al., Cellular and Molecular Immunology, 2d ed, p156)Antigens, Differentiation: Antigens expressed primarily on the membranes of living cells during sequential stages of maturation and differentiation. As immunologic markers they have high organ and tissue specificity and are useful as probes in studies of normal cell development as well as neoplastic transformation.CD4-Positive T-Lymphocytes: A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes.Antigens, CD1: Glycoproteins expressed on cortical thymocytes and on some dendritic cells and B-cells. Their structure is similar to that of MHC Class I and their function has been postulated as similar also. CD1 antigens are highly specific markers for human LANGERHANS CELLS.Antibodies, Monoclonal: Antibodies produced by a single clone of cells.Antigens, CD56: The 140 kDa isoform of NCAM (neural cell adhesion molecule) containing a transmembrane domain and short cytoplasmic tail. It is expressed by all lymphocytes mediating non-MHC restricted cytotoxicity and is present on some neural tissues and tumors.Antigens, Differentiation, T-Lymphocyte: Antigens expressed on the cell membrane of T-lymphocytes during differentiation, activation, and normal and neoplastic transformation. Their phenotypic characterization is important in differential diagnosis and studies of thymic ontogeny and T-cell function.ADP-ribosyl Cyclase: A membrane-bound or cytosolic enzyme that catalyzes the synthesis of CYCLIC ADP-RIBOSE (cADPR) from nicotinamide adenine dinucleotide (NAD). This enzyme generally catalyzes the hydrolysis of cADPR to ADP-RIBOSE, as well, and sometimes the synthesis of cyclic ADP-ribose 2' phosphate (2'-P-cADPR) from NADP.Antigens, Differentiation, Myelomonocytic: Surface antigens expressed on myeloid cells of the granulocyte-monocyte-histiocyte series during differentiation. Analysis of their reactivity in normal and malignant myelomonocytic cells is useful in identifying and classifying human leukemias and lymphomas.Antigens, CD80: A costimulatory ligand expressed by ANTIGEN-PRESENTING CELLS that binds to CTLA-4 ANTIGEN with high specificity and to CD28 ANTIGEN with low specificity. The interaction of CD80 with CD28 ANTIGEN provides a costimulatory signal to T-LYMPHOCYTES, while its interaction with CTLA-4 ANTIGEN may play a role in inducing PERIPHERAL TOLERANCE.Antigens, CD53: Tetraspanin proteins found at high levels in cells of the lymphoid-myeloid lineage. CD53 antigens may be involved regulating the differentiation of T-LYMPHOCYTES and the activation of B-LYMPHOCYTES.Antigens, CD24: A cell adhesion protein that was originally identified as a heat stable antigen in mice. It is involved in METASTASIS and is highly expressed in many NEOPLASMS.Antigens, CD13: Zinc-binding metalloproteases that are members of the type II integral membrane metalloproteases. They are expressed by GRANULOCYTES; MONOCYTES; and their precursors as well as by various non-hematopoietic cells. They release an N-terminal amino acid from a peptide, amide or arylamide.Antigens, Protozoan: Any part or derivative of any protozoan that elicits immunity; malaria (Plasmodium) and trypanosome antigens are presently the most frequently encountered.T-Lymphocytes: Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.Antigens, CD86: A costimulatory ligand expressed by ANTIGEN-PRESENTING CELLS that binds to CD28 ANTIGEN with high specificity and to CTLA-4 ANTIGEN with low specificity. The interaction of CD86 with CD28 ANTIGEN provides a stimulatory signal to T-LYMPHOCYTES, while its interaction with CTLA-4 ANTIGEN may play a role in inducing PERIPHERAL TOLERANCE.Flow Cytometry: Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.B-Lymphocytes: Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.Antigens, Polyomavirus Transforming: Polyomavirus antigens which cause infection and cellular transformation. The large T antigen is necessary for the initiation of viral DNA synthesis, repression of transcription of the early region and is responsible in conjunction with the middle T antigen for the transformation of primary cells. Small T antigen is necessary for the completion of the productive infection cycle.Antigens, CD95: A tumor necrosis factor receptor subtype found in a variety of tissues and on activated LYMPHOCYTES. It has specificity for FAS LIGAND and plays a role in regulation of peripheral immune responses and APOPTOSIS. Multiple isoforms of the protein exist due to multiple ALTERNATIVE SPLICING. The activated receptor signals via a conserved death domain that associates with specific TNF RECEPTOR-ASSOCIATED FACTORS in the CYTOPLASM.HLA Antigens: Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases.Antigens, Differentiation, B-Lymphocyte: Membrane antigens associated with maturation stages of B-lymphocytes, often expressed in tumors of B-cell origin.Antigens, CD45: High-molecular weight glycoproteins uniquely expressed on the surface of LEUKOCYTES and their hemopoietic progenitors. They contain a cytoplasmic protein tyrosine phosphatase activity which plays a role in intracellular signaling from the CELL SURFACE RECEPTORS. The CD45 antigens occur as multiple isoforms that result from alternative mRNA splicing and differential usage of three exons.Immunophenotyping: Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry.NAD+ NucleosidaseAntigens, Fungal: Substances of fungal origin that have antigenic activity.Molecular Sequence Data: Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.H-2 Antigens: The major group of transplantation antigens in the mouse.Sialic Acid Binding Ig-like Lectin 3: A 67-kDa sialic acid binding lectin that is specific for MYELOID CELLS and MONOCYTE-MACROPHAGE PRECURSOR CELLS. This protein is the smallest siglec subtype and contains a single immunoglobulin C2-set domain. It may play a role in intracellular signaling via its interaction with SHP-1 PROTEIN-TYROSINE PHOSPHATASE and SHP-2 PROTEIN-TYROSINE PHOSPHATASE.Antigens, Helminth: Any part or derivative of a helminth that elicits an immune reaction. The most commonly seen helminth antigens are those of the schistosomes.Receptors, Antigen, T-Cell: Molecules on the surface of T-lymphocytes that recognize and combine with antigens. The receptors are non-covalently associated with a complex of several polypeptides collectively called CD3 antigens (ANTIGENS, CD3). Recognition of foreign antigen and the major histocompatibility complex is accomplished by a single heterodimeric antigen-receptor structure, composed of either alpha-beta (RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA) or gamma-delta (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA) chains.Antigens, CD18: Cell-surface glycoprotein beta-chains that are non-covalently linked to specific alpha-chains of the CD11 family of leukocyte-adhesion molecules (RECEPTORS, LEUKOCYTE-ADHESION). A defect in the gene encoding CD18 causes LEUKOCYTE-ADHESION DEFICIENCY SYNDROME.Lymphocyte Activation: Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION.Membrane Glycoproteins: Glycoproteins found on the membrane or surface of cells.CD8-Positive T-Lymphocytes: A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.Epitopes: Sites on an antigen that interact with specific antibodies.Antigens, CD9: A subtype of tetraspanin proteins that play a role in cell adhesion, cell motility, and tumor metastasis. CD9 antigens take part in the process of platelet activation and aggregation, the formation of paranodal junctions in neuronal tissue, and the fusion of sperm with egg.Carcinoembryonic Antigen: A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment.HLA-DR Antigens: A subclass of HLA-D antigens that consist of alpha and beta chains. The inheritance of HLA-DR antigens differs from that of the HLA-DQ ANTIGENS and HLA-DP ANTIGENS.Antigens, CD15: A trisaccharide antigen expressed on glycolipids and many cell-surface glycoproteins. In the blood the antigen is found on the surface of NEUTROPHILS; EOSINOPHILS; and MONOCYTES. In addition, CD15 antigen is a stage-specific embryonic antigen.Antigens, Viral, Tumor: Those proteins recognized by antibodies from serum of animals bearing tumors induced by viruses; these proteins are presumably coded for by the nucleic acids of the same viruses that caused the neoplastic transformation.Cell Line: Established cell cultures that have the potential to propagate indefinitely.Antigens, CD43: A sialic acid-rich protein and an integral cell membrane mucin. It plays an important role in activation of T-LYMPHOCYTES.Antigens, CD36: Leukocyte differentiation antigens and major platelet membrane glycoproteins present on MONOCYTES; ENDOTHELIAL CELLS; PLATELETS; and mammary EPITHELIAL CELLS. They play major roles in CELL ADHESION; SIGNAL TRANSDUCTION; and regulation of angiogenesis. CD36 is a receptor for THROMBOSPONDINS and can act as a scavenger receptor that recognizes and transports oxidized LIPOPROTEINS and FATTY ACIDS.Amino Acid Sequence: The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.Antigens, CD11: A group of three different alpha chains (CD11a, CD11b, CD11c) that are associated with an invariant CD18 beta chain (ANTIGENS, CD18). The three resulting leukocyte-adhesion molecules (RECEPTORS, LEUKOCYTE ADHESION) are LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1; MACROPHAGE-1 ANTIGEN; and ANTIGEN, P150,95.Histocompatibility Antigens Class II: Large, transmembrane, non-covalently linked glycoproteins (alpha and beta). Both chains can be polymorphic although there is more structural variation in the beta chains. The class II antigens in humans are called HLA-D ANTIGENS and are coded by a gene on chromosome 6. In mice, two genes named IA and IE on chromosome 17 code for the H-2 antigens. The antigens are found on B-lymphocytes, macrophages, epidermal cells, and sperm and are thought to mediate the competence of and cellular cooperation in the immune response. The term IA antigens used to refer only to the proteins encoded by the IA genes in the mouse, but is now used as a generic term for any class II histocompatibility antigen.Histocompatibility Antigens: A group of antigens that includes both the major and minor histocompatibility antigens. The former are genetically determined by the major histocompatibility complex. They determine tissue type for transplantation and cause allograft rejections. The latter are systems of allelic alloantigens that can cause weak transplant rejection.Antigens, CD59: Small glycoproteins found on both hematopoietic and non-hematopoietic cells. CD59 restricts the cytolytic activity of homologous complement by binding to C8 and C9 and blocking the assembly of the membrane attack complex. (From Barclay et al., The Leukocyte Antigen FactsBook, 1993, p234)Receptors, Antigen, B-Cell: IMMUNOGLOBULINS on the surface of B-LYMPHOCYTES. Their MESSENGER RNA contains an EXON with a membrane spanning sequence, producing immunoglobulins in the form of type I transmembrane proteins as opposed to secreted immunoglobulins (ANTIBODIES) which do not contain the membrane spanning segment.Proliferating Cell Nuclear Antigen: Nuclear antigen with a role in DNA synthesis, DNA repair, and cell cycle progression. PCNA is required for the coordinated synthesis of both leading and lagging strands at the replication fork during DNA replication. PCNA expression correlates with the proliferation activity of several malignant and non-malignant cell types.Antigens, CD57: Oligosaccharide antigenic determinants found principally on NK cells and T-cells. Their role in the immune response is poorly understood.Antigens, CD70: A transmembrane protein belonging to the tumor necrosis factor superfamily that specifically binds to CD27 ANTIGEN. It is found on activated T-LYMPHOCYTES; B-LYMPHOCYTES; and DENDRITIC CELLS where it plays a role in stimulating the proliferation of CD4-POSITIVE T-LYMPHOCYTES and CD8-POSITIVE T-LYMPHOCYTES.Antigens, CD46: A ubiquitously expressed complement receptor that binds COMPLEMENT C3B and COMPLEMENT C4B and serves as a cofactor for their inactivation. CD46 also interacts with a wide variety of pathogens and mediates immune response.Lectins, C-Type: A class of animal lectins that bind to carbohydrate in a calcium-dependent manner. They share a common carbohydrate-binding domain that is structurally distinct from other classes of lectins.Antigens, CD58: Glycoproteins with a wide distribution on hematopoietic and non-hematopoietic cells and strongly expressed on macrophages. CD58 mediates cell adhesion by binding to CD2; (ANTIGENS, CD2); and this enhances antigen-specific T-cell activation.Antigens, CD4: 55-kDa antigens found on HELPER-INDUCER T-LYMPHOCYTES and on a variety of other immune cell types. CD4 antigens are members of the immunoglobulin supergene family and are implicated as associative recognition elements in MAJOR HISTOCOMPATIBILITY COMPLEX class II-restricted immune responses. On T-lymphocytes they define the helper/inducer subset. CD4 antigens also serve as INTERLEUKIN-15 receptors and bind to the HIV receptors, binding directly to the HIV ENVELOPE PROTEIN GP120.Antigens, CD47: A ubiquitously expressed membrane glycoprotein. It interacts with a variety of INTEGRINS and mediates responses to EXTRACELLULAR MATRIX PROTEINS.Antigens, CD11b: A CD antigen that contains a conserved I domain which is involved in ligand binding. When combined with CD18 the two subunits form MACROPHAGE-1 ANTIGEN.Base Sequence: The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.Prostate-Specific Antigen: A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.Antigens, CD11c: An integrin alpha subunit of approximately 150-kDa molecular weight. It is expressed at high levels on monocytes and combines with CD18 ANTIGEN to form the cell surface receptor INTEGRIN ALPHAXBETA2. The subunit contains a conserved I-domain which is characteristic of several of alpha integrins.O Antigens: The lipopolysaccharide-protein somatic antigens, usually from gram-negative bacteria, important in the serological classification of enteric bacilli. The O-specific chains determine the specificity of the O antigens of a given serotype. O antigens are the immunodominant part of the lipopolysaccharide molecule in the intact bacterial cell. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)HLA-A2 Antigen: A specific HLA-A surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-A*02 allele family.Enzyme-Linked Immunosorbent Assay: An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.Immunohistochemistry: Histochemical localization of immunoreactive substances using labeled antibodies as reagents.Hematopoietic Stem Cells: Progenitor cells from which all blood cells derive.CD4 Lymphocyte Count: The number of CD4-POSITIVE T-LYMPHOCYTES per unit volume of BLOOD. Determination requires the use of a fluorescence-activated flow cytometer.Immunoglobulin G: The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.Cell SeparationAntigens, Tumor-Associated, Carbohydrate: Carbohydrate antigens expressed by malignant tissue. They are useful as tumor markers and are measured in the serum by means of a radioimmunoassay employing monoclonal antibodies.Antigens, CD55: GPI-linked membrane proteins broadly distributed among hematopoietic and non-hematopoietic cells. CD55 prevents the assembly of C3 CONVERTASE or accelerates the disassembly of preformed convertase, thus blocking the formation of the membrane attack complex.Antigens, CD31: Cell adhesion molecules present on virtually all monocytes, platelets, and granulocytes. CD31 is highly expressed on endothelial cells and concentrated at the junctions between them.Tumor Cells, Cultured: Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.Histocompatibility Antigens Class I: Membrane glycoproteins consisting of an alpha subunit and a BETA 2-MICROGLOBULIN beta subunit. In humans, highly polymorphic genes on CHROMOSOME 6 encode the alpha subunits of class I antigens and play an important role in determining the serological specificity of the surface antigen. Class I antigens are found on most nucleated cells and are generally detected by their reactivity with alloantisera. These antigens are recognized during GRAFT REJECTION and restrict cell-mediated lysis of virus-infected cells.Antigens, CD81: Tetraspanin proteins that are involved in a variety of cellular functions including BASEMENT MEMBRANE assembly, and in the formation of a molecular complexes on the surface of LYMPHOCYTES.Cells, Cultured: Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.Antigens, CD137: A member of the tumor necrosis factor receptor superfamily that is specific for 4-1BB LIGAND. It is found in a variety of immune cell types including activated T-LYMPHOCYTES; NATURAL KILLER CELLS; and DENDRITIC CELLS. Activation of the receptor on T-LYMPHOCYTES plays a role in their expansion, production of cytokines and survival. Signaling by the activated receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.Cell Differentiation: Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.Recombinant Proteins: Proteins prepared by recombinant DNA technology.Lymphocytes: White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.Mice, Inbred BALB CMonocytes: Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles.HLA-A Antigens: Polymorphic class I human histocompatibility (HLA) surface antigens present on almost all nucleated cells. At least 20 antigens have been identified which are encoded by the A locus of multiple alleles on chromosome 6. They serve as targets for T-cell cytolytic responses and are involved with acceptance or rejection of tissue/organ grafts.Cross Reactions: Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen.Dendritic Cells: Specialized cells of the hematopoietic system that have branch-like extensions. They are found throughout the lymphatic system, and in non-lymphoid tissues such as SKIN and the epithelia of the intestinal, respiratory, and reproductive tracts. They trap and process ANTIGENS, and present them to T-CELLS, thereby stimulating CELL-MEDIATED IMMUNITY. They are different from the non-hematopoietic FOLLICULAR DENDRITIC CELLS, which have a similar morphology and immune system function, but with respect to humoral immunity (ANTIBODY PRODUCTION).Receptors, Interleukin-2: Receptors present on activated T-LYMPHOCYTES and B-LYMPHOCYTES that are specific for INTERLEUKIN-2 and play an important role in LYMPHOCYTE ACTIVATION. They are heterotrimeric proteins consisting of the INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT, the INTERLEUKIN-2 RECEPTOR BETA SUBUNIT, and the INTERLEUKIN RECEPTOR COMMON GAMMA-CHAIN.Blood Group Antigens: Sets of cell surface antigens located on BLOOD CELLS. They are usually membrane GLYCOPROTEINS or GLYCOLIPIDS that are antigenically distinguished by their carbohydrate moieties.Hepatitis B Surface Antigens: Those hepatitis B antigens found on the surface of the Dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen.
It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL (a type of T ... brentuximab vedotin) for Injection Archived May 25, 2013, at the Wayback Machine. (2012) Adcetris (brentuximab vedotin): Drug ... "FDA Approves Brentuximab Vedotin for CTCL". OncLive. 2017. Retrieved 2017-11-10. PBAC Meetings March 2014 - Brentuximab Vedotin ... "A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma" at ClinicalTrials.gov "Brentuximab Vedotin Shows ...
... is the target of the FDA approved therapeutic brentuximab Vedotin (Adcetris), designed and developed by Seattle Genetics. ... CD30 Antigens at the US National Library of Medicine Medical Subject Headings (MeSH) Human TNFRSF8 genome location and TNFRSF8 ... Josimovic-Alasevic O, Dürkop H, Schwarting R, Backé E, Stein H, Diamantstein T (Jan 1989). "Ki-1 (CD30) antigen is released by ... It is approved for use in: Hodgkin lymphoma (HL) (brentuximab vedotin) after failure of autologous stem cell transplant (ASCT) ...
Brentuximab vedotin includes an enzyme-sensitive cleavable linker that delivers the potent and highly toxic antimicrotubule ... The biochemical reaction between the antibody and the target protein (antigen) triggers a signal in the tumor cell, which then ... However, the combination of MMAE linked to an anti-CD30 monoclonal antibody (cAC10, a cell membrane protein of the tumor ... Brentuximab vedotin (SGN35), ADC Review/Journal of Antibody-drug Conjugates FDA Approves Genentech's Kadcyla® (Ado-Trastuzumab ...
It increases MHC II and adhesion molecules LFA-1 and LFA-3 (lymphocyte function-associated antigen). ... Tositumomab), CD30 (Brentuximab), CD52 (Alemtuzumab). *myeloid: CD33 (Gemtuzumab). Tyrosine-kinase inhibitors ("-nib"). ... Pinatuzumab vedotin§. *Polatuzumab vedotin†. *Rosmantuzumab. *Rovalpituzumab tesirine†. *Sacituzumab govitecan†. *Sibrotuzumab§ ...
... trastuzumab emtansine and brentuximab vedotin, are both in late clinical trials, and the latter has been granted accelerated ... The antibody will be targeted at a preferentially expressed protein in the tumour cells (known as a tumor antigen) or on cells ... They bind to the tumor antigen and are internalised, where the linker releases the drug into the cell. These specially targeted ... Tositumomab), CD30 (Brentuximab), CD52 (Alemtuzumab). *myeloid: CD33 (Gemtuzumab). Tyrosine-kinase inhibitors ("-nib"). ...
Antigens, CD30. Lymphoma. monomethylauristatin E. Drug Therapy. CD30-expression. PTCL. Additional relevant MeSH terms:. Layout ... Experimental: Part B: Brentuximab Vedotin + Dacarbazine in HL Patients Drug: brentuximab vedotin 1.8 mg/kg every 3 weeks by IV ... Experimental: Part D: Brentuximab Vedotin + Nivolumab in HL Patients Drug: brentuximab vedotin 1.8 mg/kg every 3 weeks by IV ... Experimental: Part A: Brentuximab Vedotin in HL Patients Drug: brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion ...
Antigens, CD30. Antibody-Drug Conjugate. Antibodies, Monoclonal. Disease, Hodgkin. Drug Therapy. Hematologic Diseases. ... brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion. Drug: brentuximab vedotin Every 21 days by IV infusion (1.8 mg/kg) ... Drug: brentuximab vedotin Drug: placebo Phase 3 Expanded Access : An investigational treatment associated with this study is ... A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell ...
Antigens, CD30. Drug Therapy. Hematologic Diseases. Immunotherapy. Monomethylauristatin E. Additional relevant MeSH terms: ... A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study. The safety and ... CD30-positive hematologic malignancy.. *At a minimum, experienced clinical benefit in the prior brentuximab vedotin study. For ... Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol. 2014 Mar 19;7:24 ...
Antigens, CD30. Antibody-Drug Conjugate. Antibodies, Monoclonal. Immunotherapy. Autologous stem cell transplant. ... Experimental: Brentuximab Vedotin + Nivolumab Brentuximab vedotin plus nivolumab. Drug: brentuximab vedotin 1.8 mg/kg by ... A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma. The safety and scientific ... Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. ...
Brentuximab Vedotin) for the Treatment of Relapsed or Refractory Hodgkin Lymphoma (HL) and Systemic Anaplastic Large Cell ... CD30-expressing cells, resulting in target cell death. The CD30 antigen is known to be expressed on the Reed-Sternberg cells of ... ADCETRIS (brentuximab vedotin) was issued marketing authorization under the NOC/c policy based on results from a single-arm, ... consists of a monoclonal antibody directed to an antigen called CD30. The monoclonal antibody is connected to a cell-killing ...
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812-1821.. View this article via ... Targeting CD30 with T cells expressing a CD30-specific chimeric antigen receptor (CAR) may reduce the side effects and augment ... for CD30. No chemotherapy was given to patients immediately before or after infusion of CD30.CAR-transduced T cells (CD30.CAR- ... Soluble CD30 (sCD30) is typically elevated in advanced HL (30). Although CD30.CAR-Ts are not blocked by sCD30 (26, 31), we ...
A defining attribute of the Reed-Sternberg cell is its expression of the CD30 antigen. Globally, more than 30,000 cases of ... brentuximab vedotin). ADCETRIS™ (brentuximab vedotin) is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal ... Brentuximab Vedotin) in Hodgkin Lymphoma at EHA Annual Meeting. Update: Adcetris (brentuximab vedotin) Now FDA Approved - ... Home › News › Clinical Trials › Millennium and Seattle Genetics Present Clinical Data on ADCETRIS (Brentuximab Vedotin) in ...
... which comprise only a minority of cells in the tumor mass and express CD30 surface antigen (6). Alternatively, ALCL is ... CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin. Robert ... Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure. Leuk Lymphoma 2012 ... CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin ...
Brentuximab vedotin (BV) was used to select several CD30-expressing cell models for drug resistance. The ALCL cell model Karpas ... complementary studies with resistant models to brentuximab vedotin demonstrate that the same ADC can induce either antigen ... Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel ... Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure. Leuk Lymphoma 2012 ...
Upon binding to the target antigen, brentuximab vedotin is internalized and subsequently degraded within the lysosomal ... the role of brentuximab vedotin as maintenance in high-risk patients and the challenge brentuximab vedotin poses to allogeneic ... 4 the CD30 antigen has attracted substantial scientific interest. Initially termed Ki-1, this antigen was clustered as CD30 ... Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812-21. ...
It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL (a type of T ... brentuximab vedotin) for Injection Archived May 25, 2013, at the Wayback Machine. (2012) Adcetris (brentuximab vedotin): Drug ... "FDA Approves Brentuximab Vedotin for CTCL". OncLive. 2017. Retrieved 2017-11-10. PBAC Meetings March 2014 - Brentuximab Vedotin ... "A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma" at ClinicalTrials.gov "Brentuximab Vedotin Shows ...
Brentuximab vedotin (Adcetris®), an antibody that targets the CD30 antigen (found on lymphocytes), attached to a chemo drug ... Most naked mAbs attach to antigens on cancer cells, but some work by binding to antigens on other, non-cancerous cells, or even ... Some mAbs can have side effects that are related to the antigens they target. For example:. *Bevacizumab (Avastin®) is an mAb ... An antibody is a protein that sticks to a specific protein called an antigen. Antibodies circulate throughout the body until ...
... antibody-drug conjugate with a high selectivity against CD30+ cell lines and more than 300-fold less activity against antigen- ... Brentuximab vedotin (SGN-35) is an antibody-drug conjugate with a high selectivity against CD30+ cell lines and more than 300- ... Increased Efficacy of Brentuximab Vedotin (SGN-35) in Combination with Cytokine-Induced Killer Cells in Lymphoma. Laura Esser 1 ... "Increased Efficacy of Brentuximab Vedotin (SGN-35) in Combination with Cytokine-Induced Killer Cells in Lymphoma." Int. J. Mol ...
The Takeda Oncology Company Announce Strategic Collaboration for Novel Late-Stage Lymphoma Program Brentuximab Vedotin (SGN-35 ... About Brentuximab Vedotin. Brentuximab vedotin is an ADC targeting CD30 utilizing Seattle Genetics proprietary technology. ... Earlier this year, Millennium obtained an exclusive license to Seattle Genetics ADC technology for an antigen expressed on ... Brentuximab vedotin is currently being investigated in patients with relapsed or refractory HL or systemic ALCL. Brentuximab ...
... successfully treated with sixteen cycles of brentuximab vedotin. This could be a more effective approach with a less ... Histopathologically and microscopically, PCALCL exhibits a high expression rate of CD30+ antigen (CD30 positivity is required ... R. Dummer, Y. H. Kim, S. M. Horwitz et al., "Brentuximab vedotin or physicians choice in CD30-positive cutaneous T-cell ... R. Stranzenbach, E. Dippel, M. Schlaak, and R. Stadler, "Brentuximab vedotin in CD30+ cutaneous lymphoma: how do we treat, how ...
Brentuximab vedotin is directed against the CD30 antigen, a protein expressed on the surface of some T-cell lymphomas. The ... with the recent exception of brentuximab vedotin which is directed against the CD30 antigen expressed in some T-cell lymphomas ... Brentuximab vedotin (SGN-35) in patients with relapsed or refractory anaplastic large-cell lymphoma: results of a phase II ... Although effective, brentuximab vedotin is associated with toxicity with sensory neuropathy a particular issue often requiring ...
... antibody-drug linker chemistry that has led to Food and Drug Administration approval of ADCs such a brentuximab vedotin (anti- ... Unfortunately almost all of the antigens that are recognized by antibodies and ADCs are not exclusively expressed on cancer ... CD30-MMAE) and ado-trastuzumab emtansine (anti-HER2-DM1). Several ADCs are currently in clinical trials for prostate cancer, ... including both a prostate-specific membrane antigen (PSMA) antibody (3⇓-5) and an SCL44A4 antibody (6, 7) conjugated to the ...
CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin. Mol ... Many ADCs currently in clinical development have been designed to target human tumor cell antigens and do not cross-react with ... Brentuximab vedotin (Adcetris), monomethyl auristatin E-linked (MMAE-linked) anti-CD30 ADC, is used for the treatment of ... the same drug-linker design used for clinically approved brentuximab vedotin. The cathepsin B site was incorporated into the ...
Brentuximab vedotin: a review in CD30-positive Hodgkin lymphoma. Drugs (2017) 77(4):435-45. doi:10.1007/s40265-017-0705-5 ... Other two antibodies identify antigens expressed by B cells and by other cells of the immune system, including an anti-CD30 mAb ... Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin. Leuk Res (2016) 44:25-31. doi:10.1016/j.leukres. ... Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells. Expert Opin Investig Drugs (2011) 20(1):99-105 ...
However the monoclonal antibody Brentuximab Vedotin is used for T-cell lymphoma. It targets the CD30 antigen found on most ALCL ... Patients expressing the CD30 antigen generally have a more favourable prognosis, as do patients who express the Anaplastic ... Phase 3 trial of brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients (pts) with CD30+ mature T-cell ... Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in a phase I dose- ...
Brentuximab vedotin is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and ... It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL (a type of T ... It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL (a type of T ...
... some B-cell lymphomas and brentuximab vedotin in Hodgkin lymphoma and the non-Hodgkin lymphomas that express the CD30 antigen, ...
Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level Not Recruiting The purpose ... with brentuximab vedotin in participants with cluster of differentiation antigen 30 positive (CD30+) cutaneous T-cell lymphoma ... Exploratory study of brentuximab vedotin (SGN-35), a novel monoclonal antibody-drug-conjugate against CD30, in mycosis ... Brentuximab Vedotin Demonstrates Significant Clinical Activity in Relapsed or Refractory Mycosis Fungoides with Variable CD30 ...
... and brentuximab vedotin (anti-CD30, Adcetris®, Seattle Genetics). Parameters that impact on the pharmacokinetic and safety ... This can be either through non-tumor antigen expression in normal tissues (Hinrichs and Dixit 2015) or antigen-independent ... and brentuximab vedotin (anti-CD30, Adcetris®, Seattle Genetics). Parameters that impact on the pharmacokinetic and safety ... 2016). For example, early data from phase 1/2 trials of brentuximab vedotin with nivolumab (anti-PD-1) have demonstrated a ...
CD30 (brentuximab vedotin), CD33 (gemtuzumab), CD38 (daratumumab) and CD52 (alemtuzumab) which are expressed on B cells, ... Cancer-germline antigens include NY-ESO-1 and MAGE-A3, among others; pigment antigens include MART-1, gp100 and tyrosinase ... Under the selective pressure of an antigen-specific immune response, outgrowth of cancer cells lacking the target anti-gen ... This stands in sharp contrast to what is typically observed with tissue differentiation antigens, in which antigen expression ...
  • In August 2011, the U.S. FDA granted accelerated approval to the biologics license application (BLA) submitted by Seattle Genetics for the use of brentuximab vedotin in the treatment of relapsed HL and ALCL. (wikipedia.org)
  • BOTHELL, Wash. & CAMBRIDGE, Mass. & OSAKA, Japan, Dec 15, 2009 (BUSINESS WIRE) -- Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE: 4502) today jointly announced that Seattle Genetics and Millennium have entered into an agreement to globally develop and commercialize brentuximab vedotin (SGN-35). (fiercebiotech.com)
  • Under the collaboration, Seattle Genetics will receive an upfront payment of $60 million and retains full commercialization rights for brentuximab vedotin in the United States and Canada. (fiercebiotech.com)
  • Seattle Genetics is entitled to receive progress- and sales-dependent milestone payments in addition to tiered double-digit royalties based on net sales of brentuximab vedotin within the Takeda Group's licensed territories. (fiercebiotech.com)
  • Earlier this year, Millennium obtained an exclusive license to Seattle Genetics' ADC technology for an antigen expressed on solid tumors, as well as options for two other licenses. (fiercebiotech.com)
  • Brentuximab vedotin is an ADC targeting CD30 utilizing Seattle Genetics' proprietary technology. (fiercebiotech.com)
  • SGN-35 is an ADC comprising an anti-CD30 antibody attached by an enzyme cleavable linker to a potent, synthetic drug payload, monomethyl auristatin E (MMAE), using Seattle Genetics' proprietary technology. (ptcommunity.com)
  • This approach has been augmented by the recent Food and Drug Administration (FDA) approval of brentuximab vedotin (Adcentis, Seattle Genetics) targeting CD30 , and ado-trastuzumab emtansine (T-DM1, Roche) targeting human epidermal growth factor receptor 2 (HER2) metastatic breast cancer in 2011 and 2013, respectively. (ukdiss.com)
  • That's different from the b. vedotin collaboration, in which Seattle Genetics has retained US and Canadian commercial rights, with Takeda/Millennium responsible in the rest of the world. (blogspot.com)
  • We continue to evaluate brentuximab vedotin in combination with novel therapies, such as checkpoint inhibitors, with the goal of identifying new options for CD30-expressing lymphomas where there is high unmet need," said Roger Dansey, MD, Chief Medical Officer at Seattle Genetics. (oncozine.com)
  • Seattle Genetics, Inc. (Nasdaq:SGEN) today announced dosing of the first patient in the phase 2 innovaTV 204 clinical trial evaluating the efficacy, safety and tolerability of tisotumab vedotin as monotherapy for patients with recurrent and/or metastatic cervical cancer who have relapsed or progressed after standard of care treatment. (biospace.com)
  • With the initiation of this phase 2 study of tisotumab vedotin for women with previously treated recurrent and/or metastatic cervical cancer, we now have four late-stage development programs on registrational pathways to achieve our goal of becoming a global, multi-product oncology company," said Roger Dansey, M.D., Chief Medical Officer at Seattle Genetics. (biospace.com)
  • Receptor-engineered T cells have the potential to cause lethal toxicity from on-target recognition of normal tissues, and there is a paucity of truly tumor-specific antigens shared across tumor types. (investorvillage.com)
  • Gammaretroviral and lentiviral vectors have been used most commonly in antigen receptor gene therapy trials. (investorvillage.com)
  • We recently reported that CD4 + T cells expressing CD30, a cell-surface membrane protein and a member of the tumor necrosis factor receptor superfamily, were enriched in HIV-1 RNA, and that CD30 and HIV-1 transcriptional activity strongly colocalized in gut tissue from ART-suppressed individuals. (ashpublications.org)
  • In a paper published in the Journal of Clinical Investigation , researchers describe promising results obtained with CAR T cells engineered to recognize CD30, a receptor expressed by non-Hodgkin's lymphomas. (thebodypro.com)
  • In this review, we will retrace the relevant clinical trials investigating ADCs in GI cancers, especially ADCs targeting human epidermal growth receptor 2, mesothelin, guanylyl cyclase C, carcinogenic antigen-related cell adhesion molecule 5 (also known as CEACAM5) and other GI malignancy specific targets. (cdrjournal.com)
  • CD30, a surface protein belonging to the tumor necrosis factor receptor family and releasing from cell surface as a soluble form (sCD30) after activation, marks a subset of activated T cells secreting IFN- when exposed to allogeneic antigens. (techbizstrategy.com)
  • CD30, a cell-surface molecule belonging to the tumor necrosis factor receptor superfamily, is mainly expressed by activated T cells in the physiological condition . (techbizstrategy.com)
  • CD30, also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family and tumor marker. (wikipedia.org)
  • T cells require binding of their T cell receptor (TCR) to the peptide/human leukocyte antigen complex (pHLA) that is expressed on the target, as well as binding of the T cell costimulatory receptors to their cognate ligands that are expressed by the tumor or antigen presenting cell (APC). (aspetjournals.org)
  • (9) Rituximab is not used because it targets the CD20 antigen found only on B-cells. (nhlcyberfamily.org)
  • CD30 may be useful as a prognostic marker in rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) treated DLBCLs, indicating favorable outcomes in a Chinese population. (nih.gov)
  • This is an antibody against the CD20 antigen, which is found on lymphocytes called B cells. (cancer.org)
  • One (20%) and four (80%) patients with PEL and six (100%) and zero (0%) patients with HHV8-unrelated BCBL were positive for CD20 and CD30 expression, respectively. (e-crt.org)
  • A possible trend was detected among LANA1, CD20, and CD30 expression in BCBL. (e-crt.org)
  • The REAL Classification of Lymphoid Neoplasms proposed separating NLPHL (CD15-, CD20+, CD30-) from lymphocyte-rich classical HL (CD15+, CD20-, CD30+), on the basis of these immunophenotypic differences. (uni-bonn.de)
  • This approach is intended to spare non-targeted cells and thus may help minimize the potential toxic effects of traditional chemotherapy while allowing for the selective targeting of CD30-expressing cancer cells, thus potentially enhancing the antitumor activity. (drugs.com)
  • The Australian PBAC (Pharmaceutical Benefits Advisory Committee) considered a March 2014 application by the manufacturer for inclusion of Brentuximab Vedotin under a Pharmaceutical Benefits Scheme Section 100 (Efficient Funding of Chemotherapy) arrangement. (wikipedia.org)
  • Targeted therapy with brentuximab vedotin, either alone or in combination with chemotherapy, resulted in a sustained, long-lasting remission in both cases. (vestnikdv.ru)
  • This has changed with the success of the anti-CD30 antibody conjugated with an antitubulin agent, brentuximab vedotin, recently approved for the treatment of adult patients with relapsed or refractory CD30+ HL following autologous stem cell transplantation (ASCT) or following at least two prior therapies when ASCT or for which multi-agent chemotherapy is not a treatment option. (ovid.com)
  • Many chemotherapy regimens for B-cell NHL include the monoclonal antibody a substance made by B-lymphocytes that reacts with antigens on toxins, bacteria and some cancer cells and either kills or marks them for removal. (lymphoma.org)
  • In this paper, we describe an unusual case of oral localization, recurring after skin-involving radiotherapy, successfully treated with sixteen cycles of brentuximab vedotin. (hindawi.com)
  • We here demonstrate that the dolastatin family of microtubule inhibitors, from which the cytotoxic component of brentuximab vedotin is derived, comprises potent inducers of phenotypic and functional DC maturation. (biomedcentral.com)
  • In addition to the direct cytotoxic effect on tumour cells, dolastatins efficiently promoted antigen uptake and migration of tumour-resident DCs to tumour-draining lymph nodes. (biomedcentral.com)
  • ADCs combine a tumour-antigen specific mAb with a cytotoxic drug (or "payload") using a linker. (cdrjournal.com)
  • ADCs exert their cytotoxic effects after the mAb directly binds to a tumour specific antigen and the ADC complex is internalized into the tumour cell. (cdrjournal.com)
  • ADC refers to the delivery of cytotoxic drug compounds selectively using an antibody to tumor-associated antigens [1, (ukdiss.com)
  • Aberrant loss of pan-T-cell antigen expression is common, and about two-thirds of cases express cytotoxic proteins (TIA1, granzyme B, or perforin) (Savage, Harris et al. (atlasgeneticsoncology.org)
  • Cytotoxic-T-lymphocyte antigen (CTLA-4) and programmed cell death protein 1 (PD-1) are the two most commonly targeted immune checkpoint molecules. (aspetjournals.org)
  • Although there are several immune checkpoint pathways that regulate immune cells, to date, the two major approaches to immune checkpoint blockade that have been investigated clinically have targeted cytotoxic-T-lymphocyte antigen (CTLA-4) and the programmed cell death pathway. (aspetjournals.org)
  • Antibody-drug conjugates utilize the antibody as a delivery vehicle for highly potent cytotoxic molecules with specificity for tumor-associated antigens for cancer therapy. (biomolther.org)
  • 11 , 12 However, most of these first- and second-generation anti-CD30 immunoconjugates were either too immunogenic or not effective enough for further clinical development. (haematologica.org)
  • A phase III clinical trial is currently comparing the two combination therapies (CHOP and CHP-brentuximab vedotin) with estimated completion in December 2017. (wikipedia.org)
  • Our data reveal a novel mechanism of action for dolastatins and provide a strong rationale for clinical treatment regimens combining dolastatin-based therapies, such as brentuximab vedotin, with immune-based therapies. (biomedcentral.com)
  • Now "presenting" the antigen, the dendritic cells are administered back into the patient to induce a potent, cell-mediated anticancer immune response resulting in tumor shrinkage and clinical benefit. (scientificamerican.com)
  • The data presentations at the annual meeting reinforces our strong commitment to the brentuximab vedotin clinical development program, potentially moving into new patient populations and novel combination treatment strategies," Dansey added. (oncozine.com)
  • Kadcyla, which targets the HER2 antigen, is being evaluated in seven Phase III clinical trials, as well as in earlier-stage trials. (drug-dev.com)
  • For more information about the phase 2 innovaTV 204 clinical trial of tisotumab vedotin, please visit www.clinicaltrials.gov , (Identifier: NCT03438396). (biospace.com)
  • The results of these studies have been published in the Journal of Clinical Oncology , which also demonstrated a favorable safety profile with the autologous CD30 CAR T-cell therapy. (targetedonc.com)
  • Gene engineering obviates the requirement for surgery because T cells can be isolated from the blood and receptors conveying specificity for tumor-associated antigens can be introduced using viral and non-viral integration techniques22. (investorvillage.com)
  • 16 This mechanism of action explains the high specific potency of this construct, both in preclinical in-vitro models as well as in animals bearing human Hodgkin's and other CD30-positive xenografts. (haematologica.org)
  • When combining dolastatins with tumour-antigen-specific vaccination or blockade of the PD-1/PD-L1 and CTLA-4 co-inhibitory pathways, we observed substantial therapeutic synergies. (biomedcentral.com)
  • Through activation of co-stimulatory receptors, or antagonization of inhibitory signals, T-cell responses toward tumor antigens can be enhanced and represent an exciting cancer therapeutic strategy that is transforming the oncology world. (onclive.com)
  • As researchers have found more antigens linked to cancer, they have been able to make mAbs against more and more cancers. (cancer.org)
  • However, brentuximab vedotin (BV) was recently included in the National Comprehensive Cancer Network Guidelines as a first line treatment. (hindawi.com)
  • This success has captured public imagination and driven academic and industrial researchers to develop similar 'off-the-shelf' receptors targeting shared antigens on epithelial cancers, the leading cause of cancer-related deaths. (investorvillage.com)
  • These include selection of true cancer cell specific antigens, enhanced recruitment of bystander cell killing mechanisms, and development of more economic production technologies. (biomedcentral.com)
  • Therefore, targeted therapy for the tumor-specific antigens has become an invaluable tool in cancer therapy. (biomolther.org)
  • In a prior study, tisotumab vedotin demonstrated encouraging results in previously treated recurrent and/or metastatic cervical cancer, an area of unmet need where there is no established standard of care and response rates are limited. (biospace.com)
  • Upregulated expression of CD30 is commonly found in sclerosing angiomatoid nodular transformation of the spleen. (nih.gov)